Top Story

Aprepitant regimen reduced CINV in post-transplant myeloma

October 21, 2014

The addition of the NK-1 antagonist aprepitant to granisetron and dexamethasone reduced nausea and vomiting among patients with myeloma who underwent high-dose chemotherapy and autologous stem cell transplantation, according to results of a randomized, phase 3 trial.

The analysis included 362 patients with myeloma who melphalan conditioning followed by autologous stem cell transplantation at Heidelberg University Hospital in Germany. All patients were aged 18 years or older.

In the Journals

Panobinostat regimen extended PFS in multiple myeloma

October 20, 2014
The addition of panobinostat to bortezomib and dexamethasone significantly extended PFS among patients with relapsed or relapsed/refractory multiple myeloma, according…
figure Institution Notes

ASH elects four executive committee members

October 18, 2014
ASH elected four new members to its executive committee, the organization’s governing body.Kenneth C. Anderson, MD, will serve a 1-year term as vice president…
figure In the Journals

CTL019 therapy conferred 90% remission rate in relapsed, refractory ALL

October 15, 2014
Chimeric antigen receptor-modified T cells that target CD19 induced complete remissions in 90% of pediatric and adult patients with relapsed and refractory acute…
CME
figure

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates - Monograph

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
CME CNE
figure

Treatment Decision-Making through the Spectrum of MDS: Case 3 Stem Cell Transplant for MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »

Filter By:

In the Journals

Aprepitant regimen reduced CINV in post-transplant myeloma

October 21, 2014
The addition of the NK-1 antagonist aprepitant to granisetron and dexamethasone reduced nausea and vomiting among patients with myeloma who underwent…
In the Journals

Panobinostat regimen extended PFS in multiple myeloma

October 20, 2014
The addition of panobinostat to bortezomib and dexamethasone significantly extended PFS among patients with relapsed or relapsed/refractory multiple…
figure Institution Notes

ASH elects four executive committee members

October 18, 2014
ASH elected four new members to its executive committee, the organization’s governing body.Kenneth C. Anderson, MD, will serve a 1-year term as…
figure In the Journals

CTL019 therapy conferred 90% remission rate in relapsed, refractory ALL

October 15, 2014
Chimeric antigen receptor-modified T cells that target CD19 induced complete remissions in 90% of pediatric and adult patients with relapsed and…
figure FDA News

FDA grants priority review to blinatumomab for ALL

October 10, 2014
The FDA granted priority review status to blinatumomab, an investigational agent intended for the treatment of adults with Philadelphia…
FDA News

FDA approves Velcade regimen for treatment-naive mantle cell lymphoma

October 9, 2014
The FDA today approved the use of bortezomib as part of a combination regimen for patients with previously untreated mantle cell lymphoma, the…
figure Meeting News Coverage

International Myeloma Foundation addresses Congress on toxins at Ground Zero

September 30, 2014
On Sept. 10, the International Myeloma Foundation hosted a congressional briefing to raise awareness on the connection between environmental exposure…
Meeting News Coverage

Mild liver disease common at lymphoma diagnosis in HCV patients

September 25, 2014
NEW YORK — Patients with hepatitis C virus infection often showed signs of mild liver disease when diagnosed with HCV-associated B-cell…
figure Cover Story Publication Exclusive

Quest for clinically meaningful PFS benefit an ‘imperfect science’

HemOnc Today, September 25, 2014
Small improvements in study endpoints often serve as the foundation for drug approvals.However, a small but vocal segment of the hematology and…
figure In the Journals

Anti-CD19 CAR T cells show promise in chemotherapy-refractory DLBCL

September 24, 2014
An infusion of anti-CD19 chimeric antigen receptor T cells induced remission in the majority of patients with chemotherapy-refractory diffuse large…
More Headlines »